• Synthetic Efferocytic Microglia for Alzheimer’s Disease

  2026-08-24

  Shao and colleagues engineered a synthetic efferocytic receptor that redirects microglia toward amyloid-β clearance while limiting inflammatory signaling. Delivered through microglia-editing mRNA lipid nanoparticles, the receptor improved pathology-associated and behavioral outcomes in an Alzheimer’s disease mouse model, while also reducing synapse loss.

• Amikacin Sulfate: Intracellular Assays and Delivery

  2026-08-24

  Amikacin Sulfate supports a practical workflow spanning antimicrobial susceptibility, intracellular uptake, and granuloma-focused delivery studies. This guide separates product-backed observations from recommended assay conditions and uses KR-12 peptide research to sharpen endpoint selection without overstating cross-platform evidence.

• Calpain Inhibitor II, ALLM: Protease Biology

  2026-08-23

  Calpain Inhibitor II, ALLM is a cell-permeable peptide inhibitor of calpain I, calpain II, cathepsin L, and cathepsin B. Its reported activity in human leukemia and lymphoma models supports apoptosis-focused experiments, while recent TNBC research defines a separate calpain-2–FAK regulatory context.

• Mechanical Stress, Cytoskeleton, and Autophagy

  2026-08-22

  The study shows that compression-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules provide a supporting rather than dominant function. Its combination of mechanical stimulation, cytoskeletal polymerization perturbation, fluorescence imaging, and western blotting offers a practical framework for dissecting force-sensitive autophagy in human cells.

• DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis

  2026-08-21

  Li and colleagues developed a tetrahedral DNA nanostructure interface that organizes primers for more accessible and efficient enzymatic oligonucleotide synthesis. The framework improved substrate affinity, reaction kinetics, sequence yield, and deletion-error control, and supported a 60-nucleotide DNA information-storage demonstration.

• TAK-242 Workflow for TLR4 Inflammation Studies

  2026-08-20

  TAK-242 (Resatorvid) gives researchers a selective way to test whether TLR4 drives cytokine release, autophagy, or neuroinflammatory responses. This practical workflow connects LPS benchmark assays with pathogen-derived stimuli while emphasizing solvent control, timing, and orthogonal readouts.

• Imipenem Workflows for Antibacterial Research

  2026-08-20

  Imipenem supports complementary bacterial susceptibility, resistance-selection, immune-response, and sepsis animal model workflows from one broad-spectrum research reagent. This guide translates its PBP-directed activity into practical assay design, preparation controls, and troubleshooting strategies while keeping cross-study comparisons scientifically bounded.

• BMS-345541 Hydrochloride: Mapping IKK–RIPK1

  2026-08-19

  Explore how the IKK inhibitor BMS-345541 hydrochloride can distinguish NF-κB transcriptional control from RIPK1-driven cell death. This mechanistic framework supports more informative inflammation research and apoptosis induction in T-ALL assays.

• Gemcitabine HCl in MRI-Guided PDAC Research

  2026-08-19

  Gemcitabine HCl offers a direct mechanistic anchor for DNA replication inhibition and apoptosis induction in pancreatic cancer models. When paired with longitudinal, multianimal MRI, it supports a more efficient translational workflow that connects in vitro cytotoxicity testing with tumor growth suppression and treatment-response measurement.

• GSK343 as a Causal Probe of Tumor Immunogenicity

  2026-08-18

  GSK343 is a selective EZH2 inhibitor for dissecting H3K27me3-dependent gene repression in cancer models. This article explains how to use it alongside the CBX2–RACK1–HDAC1 mechanism to distinguish canonical PRC2 signaling from epigenetic control of tumor immunogenicity.

• Gemini QACs: Broad-Spectrum Biocidal Design

  2026-08-18

  The reference study synthesized 16 octenidine-derived gemini quaternary ammonium compounds and evaluated their antibacterial, antibiofilm, antifungal, virucidal, and cytotoxic profiles. Several derivatives outperformed octenidine and benzalkonium chloride in selected assays, while compounds 1 and 12 offered particularly informative combinations of fungal selectivity, broad activity, and reduced cytotoxicity.

• FK866 in Macrophage Host-Defense Assays

  2026-08-17

  Explore how FK866 (APO866) can be used to interrogate NAMPT-dependent macrophage antibacterial responses without confusing host protection with drug-induced toxicity. This article connects NAD metabolism, AML research, and pathogen-adaptive assay design.

• DDX23, Caspases, and SVA Immune Evasion

  2026-08-17

  A 2025 Journal of Virology study shows that DDX23 restricts Senecavirus A (SVA) through caspase-dependent degradation of viral 3A, while SVA 2B promotes DDX23 loss to counter host antiviral defense. The work combines gain- and loss-of-function experiments, caspase-pathway perturbation, and reverse genetics to connect specific viral amino acids with replication phenotypes.

• Protease Inhibitor Cocktail: EDTA-Free Workflow

  2026-08-16

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic loss during cell lysis, protein extraction, immunoprecipitation, and related assays. Its EDTA-free composition suits cation-sensitive workflows, but it should not be treated as a complete substitute for phosphatase inhibitors or as universal coverage for every protease class.

• Epoxomicin Proteasome Inhibitor Workflows

  2026-08-15

  Use Epoxomicin as a selective, irreversible proteasome inhibitor to connect protein degradation measurements with RIPK3-dependent inflammatory signaling. This practical guide covers stock preparation, cell-based assay design, viral immune-evasion studies, and troubleshooting controls that separate target engagement from nonspecific proteotoxicity.

8598 records 1/574 page Next 12345 下5页 Last page